Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel A Hamstra

Showing results (21-30 of 130) with videos related to

Pageof 13
Sort By:
Molecular and Clinical Oncology|April 29, 2014
Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiationMark Shilkrut, Angela Wu, Dafydd G Thomas, et al.
Oncology (Williston Park, N.Y.)|August 20, 2010
Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversyAnn Raldow, Daniel A Hamstra, Sung Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Do not count out external-beam radiation therapy for high-risk prostate cancerDaniel A Hamstra, Jeff M Michalski, Mack Roach, et al.
Cancer Treatment Reviews|July 30, 2010
Adjuvant radiotherapy after radical prostatectomy: evidence and analysisAnn Raldow, Daniel A Hamstra, Sung N Kim, et al.
The Lancet. Oncology|April 4, 2014
Complications of prostate cancer treatmentRonald C Chen, Daniel A Hamstra, Howard M Sandler, et al.
American Journal of Clinical Oncology|December 2, 2014
High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal TherapyChristina H Son, Daniel A Hamstra, Felix Y Feng, et al.
American Journal of Clinical Oncology|February 13, 2014
Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation TherapyMark Shilkrut, Patrick W McLaughlin, Gregory S Merrick, et al.
Cancer|October 20, 2011
Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancerNirav S Kapadia, Karin Olson, Howard M Sandler, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|December 23, 2011
Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancerMatthew H Stenmark, Karen Vineberg, Randall K Ten Haken, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancerFelix Y Feng, Kevin Blas, Karin Olson, et al.
Pageof 13

Showing results (21-30 of 130) with videos related to

Sort By:
Pageof 13
Molecular and Clinical Oncology|April 29, 2014
Expression of ribonucleoside reductase subunit M1, but not excision repair cross-complementation group 1, is predictive in muscle-invasive bladder cancer treated with chemotherapy and radiationMark Shilkrut, Angela Wu, Dafydd G Thomas, et al.
Oncology (Williston Park, N.Y.)|August 20, 2010
Salvage external beam radiotherapy for prostate cancer after radical prostatectomy: current status and controversyAnn Raldow, Daniel A Hamstra, Sung Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2010
Do not count out external-beam radiation therapy for high-risk prostate cancerDaniel A Hamstra, Jeff M Michalski, Mack Roach, et al.
Cancer Treatment Reviews|July 30, 2010
Adjuvant radiotherapy after radical prostatectomy: evidence and analysisAnn Raldow, Daniel A Hamstra, Sung N Kim, et al.
The Lancet. Oncology|April 4, 2014
Complications of prostate cancer treatmentRonald C Chen, Daniel A Hamstra, Howard M Sandler, et al.
American Journal of Clinical Oncology|December 2, 2014
High-risk Prostate Cancer Treated With Dose-escalated RT: An Analysis of Hormonal Therapy Use and Duration, and Prognostic Implications of PSA Nadir ≤0.2 to Select Men for Short-term Hormonal TherapyChristina H Son, Daniel A Hamstra, Felix Y Feng, et al.
American Journal of Clinical Oncology|February 13, 2014
Treatment Outcomes in Very High-risk Prostate Cancer Treated by Dose-escalated and Combined-Modality Radiation TherapyMark Shilkrut, Patrick W McLaughlin, Gregory S Merrick, et al.
Cancer|October 20, 2011
Interval to biochemical failure as a biomarker for cause-specific and overall survival after dose-escalated external beam radiation therapy for prostate cancerNirav S Kapadia, Karin Olson, Howard M Sandler, et al.
Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists|December 23, 2011
Dosimetric implications of residual seminal vesicle motion in fiducial-guided intensity-modulated radiotherapy for prostate cancerMatthew H Stenmark, Karen Vineberg, Randall K Ten Haken, et al.
International Journal of Radiation Oncology, Biology, Physics|March 7, 2013
Retrospective evaluation reveals that long-term androgen deprivation therapy improves cause-specific and overall survival in the setting of dose-escalated radiation for high-risk prostate cancerFelix Y Feng, Kevin Blas, Karin Olson, et al.
Pageof 13